Nuclera (NUCLERA NUCLEICS LTD.)

History

YearDetail
2013 Nuclera was founded by Michael Chen, Jiahao Huang, and Gordon Herling-McInroy at the University of Cambridge. While writing their dissertations, they identified protein inaccessibility as the number one obstacle and a key bottleneck in biology.
2021 The company acquired E Ink's digital microfluidic technology to deliver desktop protein and gene “bioprinters” for researchers in human health, agriculture, and other markets.
2022 The company expanded its offerings portfolio by establishing a new subsidiary in Boston, U.S., to deliver Nuclera’s protein desktop bioprinter to biotherapeutics, agribiotech, and other regional markets.
2023 Nuclera partnered with Google to serve the life science community by offering a higher probability of identifying de facto optimal target proteins and, in turn, extensively improving drug discovery programs.
2024 The company partnered with Sharp Life Science and licensed its digital microfluidic intellectual property portfolio for AI/ML-enabled cell-free and cell-based protein design and biomanufacturing.
AI Sentiment